Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
IDEAYA Biosciences, Inc. (IDYA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 4 Stone Paul A. (CFO) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Sold 978 shares @ $26.4003, valued at $25.8k
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/11/2023 4 Throne Jason (Chief Legal Officer) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Sold 5,000 shares @ $25.0859, valued at $125.4k
Exercised 5,000 options to buy @ $13.34, valued at $66.7k
08/11/2023 4 Stone Paul A. (CFO) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Sold 2,500 shares @ $25.0453, valued at $62.6k
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into 2027 • Initiated Phase 2/3 registrational trial for darovasertib and crizotinib combination in first-line HLA-A2 negative metastatic UM, and also initiated a separate Phase 2 clinical trial to evaluate single-agent darovasertib as neoadjuvant and adjuvant therapy for primary UM • Targeting darovasertib clinical program updates in Q4 2023, including ctDNA data from Phase 2 MUM trial at ESMO 2023, as well as prevalence of HLA-A2 / serotypes and clinical data update for darovasertib as neoadjuvant therapy in primary UM •..."
08/09/2023 144 Form 144 - Report of proposed sale of securities:
07/12/2023 4 Throne Jason (Chief Legal Officer) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Sold 9,485 shares @ $23.0024, valued at $218.2k
Exercised 4,485 options to buy @ $7.01, valued at $31.4k
Exercised 5,000 options to buy @ $12.86, valued at $64.3k
07/10/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/30/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Open Market Sales Agreement, by and between the Company and Jefferies LLC",
"Opinion of Latham & Watkins LLP"
06/09/2023 4 SHANNON TIMOTHY M (Director) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Granted 16,200 options to buy @ $25.4, valued at $411.5k
06/09/2023 4 Hampton Malcolm Garret (Director) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Granted 16,200 options to buy @ $25.4, valued at $411.5k
06/09/2023 4 Kelley Susan L. (Director) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Granted 16,200 options to buy @ $25.4, valued at $411.5k
06/09/2023 4 MACKEY CATHERINE J (Director) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Granted 16,200 options to buy @ $25.4, valued at $411.5k
06/09/2023 4 Morrison Scott W (Director) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Granted 16,200 options to buy @ $25.4, valued at $411.5k
06/09/2023 4 ROSEN TERRY J (Director) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Granted 16,200 options to buy @ $25.4, valued at $411.5k
06/09/2023 4 Stein Jeffrey (Director) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Granted 16,200 options to buy @ $25.4, valued at $411.5k
06/09/2023 4 YARNO WENDY L (Director) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Granted 16,200 options to buy @ $25.4, valued at $411.5k
06/09/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
06/02/2023 4 Throne Jason (Chief Legal Officer) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Sold 432 shares @ $23.0035, valued at $9.9k
Sold 3,553 shares @ $23.0205, valued at $81.8k
Exercised 432 options to buy @ $7.01, valued at $3k
Exercised 3,553 options to buy @ $7.01, valued at $24.9k
05/24/2023 4 Throne Jason (Chief Legal Officer) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Sold 500 shares @ $23, valued at $11.5k
Exercised 500 options to buy @ $7.01, valued at $3.5k
05/16/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma  Amended clinical trial collaboration and supply agreements with Pfizer to support evaluation of IDEAYA’s planned Phase 2/3 registrational clinical trial to evaluate Daro + Crizo in 1L MUM  Initiating Phase 2/3 registrational trial in Q2 2023 for darovasertib and crizotinib combination in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential AA South San Francisco, CA, May 16, 2023 – IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has amended its ..."
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of March 31, 2023 supplemented by $188.7 million estimated net proceeds from closing of underwritten public offering on April 27, 2023, anticipated to fund operations into 2027 • Initiating Phase 2/3 registrational trial in Q2 2023 of darovasertib and crizotinib combination in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential accelerated approval • Reported compelling darovasertib program Phase 2 clinical efficacy, including in First-Line and Any-Line MUM, and additional clinical efficacy as neoadjuvant therapy in primary UM • Targeting da..."
04/27/2023 8-K Quarterly results
04/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/24/2023 8-K Quarterly results
04/24/2023 8-K Quarterly results
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/13/2023 4 Hata Yujiro S (President and CEO) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns: Exercised 11,601 options to buy @ $4.31, valued at $50k
03/24/2023 SC 13G BIOTECHNOLOGY VALUE FUND L P reports a 5.1% stake in IDEAYA Biosciences, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy